An interventional study of Personalized Lifestyle Intervention in Depressive/Anxiety Symptoms and Depressive Disorder, sponsored by Radboud University Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Depressive Disorder with a site in Netherlands — 7 open to participants now, 9 under way, none of them phase 3. Depressive Disorder · Netherlands.
Among the 18 studies in Depressive Disorder with a site in Netherlands, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 17th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →7 of the 18 studies in Depressive Disorder with a site in Netherlands are open now. Recruiting first, the newest first:
Arkin · Sites in Netherlands
Ages 18–65
Universiteit Leiden · Sites in Netherlands
Ages 18–65
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
UMC Utrecht · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 216 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 151 across the 16 interventional studies, 216 across the 2 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 18 have an industry lead sponsor. The 10 most frequent:
Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Radboud University Medical Center has 3 studies filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
4 of the studies in Depressive Disorder with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07022184Radboud University Medical CenterLifestyle Intervention for Symptoms of Depression wIth App Support in General Practice | 2026-11 |
| NCT05640089Maastricht University Medical CenterFMRI-neurofeedback in Depression | 2027-04-30 |
| NCT07950800ArkinFrom There Towards Now; Intervention for Jewish and Indonesian Post-war Generations | 2027-08-01 |
| NCT05551468Ggz Oost BrabantStayFine: Personalised Relapse Prevention of Anxiety and Mood Disorders in Youths | 2027-11-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Depressive Disorder with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out whether a smartphone app can help reduce symptoms of depression by supporting healthy lifestyle changes and encouraging self-monitoring in adults who visit their general practitioner with symptoms of depression.
The main questions this study aims to answer are:
Does a personalized lifestyle intervention delivered through the app, in addition to regular care, reduce depression symptoms more effectively than regular care alone? Is this approach more cost-effective than regular care alone?
Researchers will compare patients who use the app alongside their regular care to patients who receive regular care without the app, to see whether the app leads to better outcomes.
Participants who use the app will:
Complete a lifestyle questionnaire focused on six themes: mental wellbeing, use of harmful substances, social relationships, healthy eating, sleep, and physical activity.
Set personal goals based on their results and receive tailored lifestyle advice.
Track their depression symptoms regularly within the app to support ongoing care.
Have follow-up conversations with their general practitioner or mental health nurse to discuss their progress.
Fill out questionnaires about their symptoms and experiences during the study.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
This study's planned enrollment of 216 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Browse Depressive Disorder studies →Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Depressive Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who visit their GP for depressive symptoms but with a PHQ-9 of \<5 at baseline are allowed to use the PLI, but will not be included in the primary analysis.
The control group, receiving care as usual, will use a version of the Patient Journey App that only displays study questionnaires and sends reminders to complete them at the start of the study, and again at 3 and 6 months. Every 6 weeks, depression symptoms are measured. Patients can view their depression questionnaire results (PHQ-9; Patient Health Questionnaire-9) in a graph within the app. General practitioners and mental health nurses will not have access to the app. At 12 months, all participants will be invited to complete an optional final questionnaire about (cost-)effectiveness to assess the long-term impact of the intervention.
The intervention group will receive the personalized lifestyle intervention (PLI) in addition to care as usual. The PLI consists of the combined use of the Patient Journey App and regular treatment provided by the general practitioner or mental health nurse in general practice. Patients, general practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes (symptoms of depression and anxiety). Study questionnaires will be completed at the start of the study (baseline), and again at 3, 6, and optionally 12 months after enrollment. Every 6 weeks, depression symptoms are measured.
Device: Personalized Lifestyle Intervention
The personalized lifestyle intervention (PLI) consists of the combined use of the Patient Journey App (PJA) alongside care provided by the general practitioner or mental health nurse. The Patient Journey App integrates four digital health tools within a single smartphone application: 1. A brief lifestyle questionnaire covering six key areas: mental wellbeing, minimizing harmful substance use, social relationships, healthy eating, sleep, and physical activity. 2. A personalized summary of the questionnaire results, which supports the formulation of two personal lifestyle goals. 3. Tailored information and advice about lifestyle, including suggested interventions, based on the patient's personal goals. 4. Monitoring of depression symptoms over time to support measurement-based care. General practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes.
Also known as: Patient Journey App, Lifestyle App, PLI
Cost-effectiveness of the Personalized Lifestyle Intervention at 6 months after baseline
To assess the PLI's cost-effectiveness from a societal perspective, the Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P) will be used. The main outcome in the cost-effectiveness analysis is Quality-Adjusted Life-Years (QALYs) based on the EQ-5D-5L, measuring general quality of life. Also, additional treatments are measured within the TIC-P, for secondary analysis on additional care.
Time frame: Baseline to 6 months
Change in quality of life using the EQ-5D-5L
Change in quality of life will be assessed using the EQ-5D-5L. This tool consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with each rated on a 5-level scale. The EQ-5D-5L also includes a visual analog scale (VAS) to assess overall health. Higher scores indicate better quality of life, while lower scores reflect greater limitations or discomfort. This measure helps track changes in health status and overall quality of life over time.
Time frame: Baseline to 6 months
Change from baseline in the mean depression severity score measured by the PHQ-9 at 6 months after baseline
To evaluate the effectiveness of the PLI on depression symptomatology, general symptoms of depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a 9-item self-reported questionnaire assessing the severity of depression symptomatology. The PHQ-9 is brief, easy to complete, and takes only a few minutes to fill out. The total score ranges from 0 to 27. Scores are interpreted as follows: 0-4 indicates minimal or no depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression. Higher scores suggest more severe symptoms, and professional treatment is recommended as the score increases.
Time frame: Baseline to 6 months.
Change in the severity of anxiety symptoms: GAD-7 (Generalized Anxiety Disorder-7)
To measure the severity of anxiety symptoms, the GAD-7 (Generalized Anxiety Disorder-7) will be used
Time frame: Baseline to 3 , 6 and 12 months
Changes in quality of life according to the Recovering Quality of Life (ReQol)
Quality of life is measured using the Recovering Quality of Life (ReQol) questionnaire, a patient-reported outcome measure specifically developed for individuals with various mental health conditions. The ReQol provides a total score ranging from 0 to 80, with higher scores reflecting a better quality of life and overall recovery outcome.
Time frame: Baseline to 3, 6 and 12 months
Change in use of antidepressants
Use of antidepressants, when started/ended, type, dosage, and at follow-up: inquire about changes.
Time frame: Baseline to 3 and 6 months
Change in use of anxiolytics
Use of anxiolytics by self-reported questions about the use of sedatives/sleep medication, when started/ended, frequency of use, type, dosage, and at follow-up: inquire about changes.
Time frame: Baseline to 3 and 6 months
Change in lifestyle measures at month 6
Self-constructed questions about the daily lifestyle habits of all participants. The lifestyle components addressed include smoking, alcohol consumption, drug use, sleep duration, adherence to the Dutch Physical Activity Guidelines according to the Dutch National Institute for Public Health and the Environment (RIVM), and nutrition based on the dietary recommendations of the Netherlands Nutrition Centre.
Time frame: Baseline to 6 months
Change in BMI
Weight and height will be combined to report BMI (Body Mass Index) in kg/m\^2.
Time frame: Baseline to 6 months
Change in lifestyle satisfaction measures at month 6 (intervention arm)
In the intervention group, self-constructed questions about lifestyle are used to measure a patient's satisfaction with specific lifestyle components on a scale from 0 to 10, where 10 indicates the highest level of satisfaction. The lifestyle components include mental wellbeing, minimizing harmful substances, social relationships, healthy eating, sleep, and physical activity. It is possible that someone smokes but is currently satisfied with this and does not wish to make any changes. The intervention is not intended to impose certain behaviors but rather to address the lifestyle components that the individual is willing and motivated to improve, with the ultimate goal of reducing depressive symptoms. These questions collectively provide an overview that the healthcare provider and patient can use together to set achievable goals. In the control group, this questionnaire will only be completed at month 6 of the study.
Time frame: Baseline (intervention only) and 6 months (both groups)
Patient satisfaction: CQi (Consumer Quality Index)
The Consumer Quality Index (CQI) is a 16-item questionnaire that evaluates patient experiences and satisfaction across various dimensions, such as communication, access to care, and treatment outcomes. The CQI helps healthcare providers track patient experiences and identify opportunities for enhancing care. It has a 5 point scale. The last item is a scoring item for overall treatment satisfaction. Higher scores indicate better satisfaction, while lower scores highlight areas for improvement.
Time frame: At 6 months
Change in patient-doctor relationship: PDRQ-9
The Patient-Doctor-Relationship Questionnaire (PDRQ-9) is a patient-reported outcome measure used to assess the quality of the therapeutic relationship between patients and their healthcare providers, such as general practitioners (GPs) or mental health nurses (GP-MHNs). The questionnaire evaluates key aspects of the patient-provider interaction, helping to capture the perceived level of trust, support, and communication. The score ranges from 9 to 45, higher score indicating a more positive relationship according to the patient.
Time frame: Baseline to 6 months
Change in social support: SSL12 (Social Support List-12)
Social support will be measured using the SSL12 (Social Support List-12) questionnaire. This validated tool assesses perceived social support across various domains, such as emotional, practical, and informational support. Higher scores indicate greater perceived social support, while lower scores suggest limited support. The SSL12 helps evaluate the level of social assistance individuals feel they receive and can track changes in social support over time.
Time frame: Baseline to 6 months
PHQ-9 at 3 and 12 months
Secondary analysis of PHQ-9 outcomes. To evaluate the effectiveness of the PLI on depression symptomatology, general symptoms of depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9) every 6 weeks. The PHQ-9 is a 9-item self-reported questionnaire assessing the severity of depression symptomatology. The PHQ-9 is brief, easy to complete, and takes only a few minutes to fill out. The total score ranges from 0 to 27. Scores are interpreted as follows: 0-4 indicates minimal or no depression, 5-9 mild depression, 10-14 moderate depression, 15-19 moderately severe depression, and 20-27 severe depression. Higher scores suggest more severe symptoms, and professional treatment is recommended as the score increases.
Time frame: Baseline to 6 weeks, 3 months and 12 months
Cost-effectiveness at 3 months and at 12 months
To assess the PLI's cost-effectiveness from a societal perspective, the Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P) will be used. The main outcome in the cost-effectiveness analysis is Quality-Adjusted Life-Years (QALYs) based on the EQ-5D-5L, measuring general quality of life. At 3 and 12 months, an incremental analysis is done in addition to the cost-effectiveness at 6 months
Time frame: baseline to 3 and 12 months
Socio-demographics at baseline
Baseline demographics include gender, age, education level, employment status and ethnicity.
Time frame: At baseline
Threatening Experiences: LTE
The List of Threatening Experiences (LTE, developed bij Brugha) measures the occurrence of 12 major categories of stressful life events (did you experience this: No, yes in the last 6 months, yes longer ago) The Dutch translation includes an additional thirteenth question: "Did you experience any other major severe negative events (yes/no)? If yes, briefly describe what happened?" The questionnaire is offered at baseline, and at 6 months a shorter version (did you experience this in the last 6 months?). Item scores are summed to derive a total score. Higher score indicates more threatening experiences.
Time frame: At enrollment and at 6 months
History of depression and previous psychological treatment
History of depression and previous psychological treatment are assessed through self-reported questions. These include the number of previous depressive episodes treated, the number of hospitalizations for depression in a psychiatric hospital or mental health institution, age of onset, duration of the current episode (when it began), family history of depression, and any previous psychological treatment or psychotherapy.
Time frame: At baseline
Chronic diseases: TIC-P
Chronic diseases will be evaluated using questions of the TIC-P questionnaire e.g., health status, lung diseases, heart diseases, blood vessels, diabetes, stroke, joint degeneration, rheumatism, cancer, high blood pressure, and other diseases.
Time frame: At baseline
Psychiatric comorbidities: LIDAS items (LIfetime Depression Assessment Self-report), adjusted.
This questionnaire comprises questions about psychiatric diagnoses and treatment (in the last 6 months , ever or never), other than depression.
Time frame: Baseline to month 6
Meta-data Patient Journey App during study
Meta-data in the Patient Journey App will be tracked and analyzed. Meta-data includes application usage data such as the frequency of app openings, the number of times patients access information, and which features or sections are most frequently used or viewed.
Time frame: At 6 and 12 months
Acceptability and usability of the app: modified MAUQ (intervention arm)
The mHealth App Usability Questionnaire (MAUQ) is a 21-item survey scored on a 7 point likert scale from 1 (disagree) to 7 (agree) with higher scores indicative of higher usability. For this study, the subscales MAUQ-E (8 items on Ease of use and satisfaction) and MAUQ-U (7 items on Usefulness) will be used.
Time frame: At 6 months (intervention arm only).
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 17 months is below that.
Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radboud University Medical Center →